Industry Resources | April 22, 2022
Medicare National Coverage Determination: Monoclonal Antibodies Directed Against Amyloid For The Treatment Of Alzheimer’s Disease (CAG-00460N) – Decision Memo
On April 7, 2022, the federal Centers for Medicare & Medicaid Services (CMS) finalized a final Medicare national coverage determination (NCD) that applies to Aduhelm, a new medication approved by the FDA to treat cognitive symptoms of Alzheimer’s disease (AD). Medicare will cover the medication class—monoclonal antibodies directed against amyloid—when used for clinical trials and comparative studies with beneficiaries with mild cognitive impairment (MCI) or dementia, when either condition is due to AD. The NCD sets out the conditions of coverage for potential clinical trials.
The NCD provisions are intended to create a predictable pathway to Medicare . . .